[ad_1]
one) 48-62% COVID-19 infection in humans is transmitted from those in the preclinical stage of the disease, i. and. of people infected but not yet sick. Therefore, you can get the infection not only from a sick person, but also from an infected person who will have symptoms after 3 days.
two) PCR Sample – Diagnostic Standard: A false-positive PCR result is rare, but a 20-67% PCR sample was taken either prematurely (within the first few days after infection) or incorrectly. patients may be false negatives. Meanwhile, serological antibody blood tests are only reliable after two weeks of illness.
3) The PCR test can remain positive for a long time, but the researchers have shown that 8 days after the onset of COVID-19 symptoms, the samples taken can no longer develop the virus in special cultures. Therefore, despite a positive PCR reaction, the chances of infecting other people on day 9 of the disease are very low.
4) 97.5 percent. In people infected with COVID-19, symptoms appear within 11 to 12 days, but generally within 5 days. If you don’t get sick within 12 days of suspected contact, your chances of getting sick are very low.
Despite their positive PCR reaction, the chances of infecting other people on day 9 of the disease are very low.
The most common symptoms of COVID-19 are fever (70-90%), dry cough (60-86%), shortness of breath (53-80%), fatigue (38%), and muscle pain (15-44%) . , nausea, vomiting or diarrhea (15-39%), headache, weakness (25%) and runny nose (7%). About 3 percent. Loss of sense of smell may be the only symptom in people with COVID-19.
6) 5 percent are seriously ill. of all patients with COVID-19 and 20%. of those hospitalized, but up to 75 percent. patients admitted to the hospital need extra oxygen. The hospital is usually admitted on the seventh day of illness. Factors that predict a more severe course of the disease include the ratio of leukocytes to lymphocytes (high white blood cells, low lymphocytes), a decrease in the number of platelets in the blood, and an increase in D-dimers.
Photo from 123RF.com / Tube
7) Remdesivir administered in intravenous infusions for 5 days shortens the duration of the disease, but its effect on mortality has not been established. Liver toxicity has been reported in a small number of patients.
8) Dexamethasone reduces mortality only in patients who have been ill for more than 7 days and require supplemental oxygen, but the benefit is greater in patients who require mechanical ventilation. The benefit of this medicine in other patients has not been established.
If you think you are taking dexamethasone prophylactically and are not getting sick, you are making a big mistake. And when you start using it at home, you can add more problems. This medication is not believed to be useful in stopping the spread of the virus in the body (rather, on the contrary), but in regulating the immune response during a developing cytokine storm. Basically it is a medicine for intensive care doctors, not for family doctors or for the patients themselves.
9) Low molecular weight heparins reduce the risk of thrombosis in COVID-19, but the prophylactic dose of these drugs is not yet fully understood. The experience with low molecular weight heparins in the Santara clinics is positive, but higher doses are often required to be successful.
If you think you are taking dexamethasone prophylactically and you don’t get sick, you are making a big mistake.
The only advice for patients is that subcutaneous injections of blood thinners may be the most important life-saving treatment for COVID-19, and should only be stopped in exceptional cases of serious side effects.
10) More than 120 candidate vaccines are considered potentially useful in preventing the spread of infection, and more than ten are already being studied in phase I-III studies. However, the problem is that the effectiveness of all possible vaccines will only be determined at the end of the year, when a greater number of cases is expected in the northern hemisphere, where the main contenders are studied.
[ad_2]
